IN2014MN00191A - - Google Patents

Info

Publication number
IN2014MN00191A
IN2014MN00191A IN191MUN2014A IN2014MN00191A IN 2014MN00191 A IN2014MN00191 A IN 2014MN00191A IN 191MUN2014 A IN191MUN2014 A IN 191MUN2014A IN 2014MN00191 A IN2014MN00191 A IN 2014MN00191A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Chafiq Hamdouchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN00191(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IN2014MN00191A publication Critical patent/IN2014MN00191A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN191MUN2014 2011-08-17 2014-01-30 IN2014MN00191A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524462P 2011-08-17 2011-08-17
PCT/US2012/050051 WO2013025424A1 (en) 2011-08-17 2012-08-09 A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes

Publications (1)

Publication Number Publication Date
IN2014MN00191A true IN2014MN00191A (cg-RX-API-DMAC7.html) 2015-08-21

Family

ID=46690732

Family Applications (1)

Application Number Title Priority Date Filing Date
IN191MUN2014 IN2014MN00191A (cg-RX-API-DMAC7.html) 2011-08-17 2014-01-30

Country Status (30)

Country Link
US (1) US8431706B2 (cg-RX-API-DMAC7.html)
EP (1) EP2744806B1 (cg-RX-API-DMAC7.html)
JP (1) JP5903162B2 (cg-RX-API-DMAC7.html)
KR (1) KR101570624B1 (cg-RX-API-DMAC7.html)
CN (1) CN103687856B (cg-RX-API-DMAC7.html)
AP (1) AP3589A (cg-RX-API-DMAC7.html)
AR (1) AR087451A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012295372A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014003079A2 (cg-RX-API-DMAC7.html)
CA (1) CA2843474C (cg-RX-API-DMAC7.html)
CL (1) CL2014000357A1 (cg-RX-API-DMAC7.html)
CO (1) CO6880069A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140052A (cg-RX-API-DMAC7.html)
DO (1) DOP2014000018A (cg-RX-API-DMAC7.html)
EA (1) EA022165B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14013211A (cg-RX-API-DMAC7.html)
ES (1) ES2578165T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400022A (cg-RX-API-DMAC7.html)
IL (1) IL230635A (cg-RX-API-DMAC7.html)
IN (1) IN2014MN00191A (cg-RX-API-DMAC7.html)
MA (1) MA35351B1 (cg-RX-API-DMAC7.html)
MX (1) MX2014001832A (cg-RX-API-DMAC7.html)
PE (1) PE20140831A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500366A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201401793PA (cg-RX-API-DMAC7.html)
TN (1) TN2014000058A1 (cg-RX-API-DMAC7.html)
TW (1) TWI537262B (cg-RX-API-DMAC7.html)
UA (1) UA110983C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013025424A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201400705B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105722841A (zh) 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3978485B1 (en) 2019-05-31 2026-02-11 Hyundai Pharm Co., Ltd. Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
EP4052790A4 (en) * 2019-10-31 2023-12-27 China Petroleum & Chemical Corporation SUPPORTED CATALYST, PRODUCTION PROCESS THEREOF AND APPLICATION THEREOF
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
CN115317484B (zh) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
JP2004529132A (ja) * 2001-03-27 2004-09-24 アクテリオン ファマシューティカルズ リミテッド 1,2,3,4−テトラヒドロイソキノリン誘導体
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2005087710A1 (ja) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
SG11201401793PA (en) 2014-09-26
UA110983C2 (uk) 2016-03-10
US20130045990A1 (en) 2013-02-21
AR087451A1 (es) 2014-03-26
ES2578165T3 (es) 2016-07-21
CL2014000357A1 (es) 2014-09-05
JP5903162B2 (ja) 2016-04-13
NZ621248A (en) 2015-08-28
GT201400022A (es) 2015-01-16
TWI537262B (zh) 2016-06-11
CR20140052A (es) 2014-06-20
MA35351B1 (fr) 2014-08-01
EP2744806A1 (en) 2014-06-25
CA2843474C (en) 2015-12-15
ECSP14013211A (es) 2014-03-31
WO2013025424A1 (en) 2013-02-21
CO6880069A2 (es) 2014-02-28
EA201490269A1 (ru) 2014-05-30
PE20140831A1 (es) 2014-07-14
DOP2014000018A (es) 2014-04-15
EA022165B1 (ru) 2015-11-30
CN103687856B (zh) 2015-07-22
CN103687856A (zh) 2014-03-26
EP2744806B1 (en) 2016-04-27
JP2014521744A (ja) 2014-08-28
TN2014000058A1 (en) 2015-07-01
ZA201400705B (en) 2015-11-25
CA2843474A1 (en) 2013-02-21
US8431706B2 (en) 2013-04-30
AP3589A (en) 2016-02-15
PH12014500366A1 (en) 2014-04-14
IL230635A (en) 2015-11-30
TW201319060A (zh) 2013-05-16
IL230635A0 (en) 2014-03-31
KR101570624B1 (ko) 2015-11-19
AU2012295372A1 (en) 2014-01-23
MX2014001832A (es) 2014-02-27
AP2014007436A0 (en) 2014-02-28
BR112014003079A2 (pt) 2017-02-21
KR20140041835A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
BR112013022641A2 (cg-RX-API-DMAC7.html)
BR112013031251A2 (cg-RX-API-DMAC7.html)
BR112013027245A2 (cg-RX-API-DMAC7.html)
BR112013024383A2 (cg-RX-API-DMAC7.html)
BR112013026905A2 (cg-RX-API-DMAC7.html)
BR112013023185A2 (cg-RX-API-DMAC7.html)
BR112013022995A2 (cg-RX-API-DMAC7.html)
BR112013017670A2 (cg-RX-API-DMAC7.html)
BR112013027830A2 (cg-RX-API-DMAC7.html)
AP3853A (cg-RX-API-DMAC7.html)
BR112013023927A2 (cg-RX-API-DMAC7.html)
BR112013027452A2 (cg-RX-API-DMAC7.html)
BR112013024365A2 (cg-RX-API-DMAC7.html)
BR112013028733A2 (cg-RX-API-DMAC7.html)
BR112013027121A2 (cg-RX-API-DMAC7.html)
AP2016009466A0 (cg-RX-API-DMAC7.html)
BR112013031556A2 (cg-RX-API-DMAC7.html)
BR112013032368A2 (cg-RX-API-DMAC7.html)
BR112013018949A2 (cg-RX-API-DMAC7.html)
BR112013032377A2 (cg-RX-API-DMAC7.html)
BR112013026895A2 (cg-RX-API-DMAC7.html)
BR112013027761A2 (cg-RX-API-DMAC7.html)
BR112013021637A2 (cg-RX-API-DMAC7.html)
BR112013025487A2 (cg-RX-API-DMAC7.html)
BR112013023266A2 (cg-RX-API-DMAC7.html)